Principles of inner ear sustained release following intratympanic administration

Laryngoscope

Volumn 121, Issue 2, 2011, Pages 385-391

  Wang, Xiaobo ^a   Dellamary, Luis ^a   Fernandez, Rayne ^a   Ye, Qiang ^a   Lebel, Carl ^a   Piu, Fabrice ^a  

^a Otonomy Inc   (United States)

Author keywords

poloxamer hydrogel; Steroids; sustained release

Indexed keywords

DEXAMETHASONE; DEXAMETHASONE ACETATE; DEXAMETHASONE SODIUM PHOSPHATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; EXPERIMENTAL GUINEA PIG; FEMALE; GELATION; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; INNER EAR; NONHUMAN; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

ANIMALS; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; EAR, INNER; GUINEA PIGS; METHYLPREDNISOLONE; POLOXAMER; STEROIDS; TYMPANIC MEMBRANE;

EID: 79251570548     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.21370     Document Type: Article

References (24)

1. Wang X, Dellamary L, Fernandez R, et al. Dose dependent sustained release of dexamethasone in inner ear cochlear fluids using a novel local delivery approach. Audiol Neurootol 2009; 14: 393-401.
2. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC., A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res 2006; 23: 2709-2728.
3. Singh-Joy SD, McLain VC., Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int J Toxicol 2008; 27 (Suppl 2): 93-128.
4. Battaglia A, Burchette R, Cueva R,. Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otol Neurotol 2008; 29: 453-460.
5. Chandrasekhar SS., Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol 2001; 22: 18-23.
6. Kopke RD, Hoffer ME, Wester D, OLeary MJ, Jackson RL., Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol Neurotol 2001; 22: 475-479.
7. Plontke SK, Lowenheim H, Mertens J, et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2009; 119: 359-369.
8. Xenellis J, Papadimitriou N, Nikolopoulos T, et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngol Head Neck Surg 2006; 134: 940-945.
9. Dodson KM, Woodson E, Sismanis A., Intratympanic steroid perfusion for the treatment of Menieres disease: a retrospective study. Ear Nose Throat J 2004; 83: 394-398.
10. Shea JJ Jr., The role of dexamethasone or streptomycin perfusion in the treatment of Menieres disease. Otolaryngol Clin North Am 1997; 30: 1051-1059.
11. Chandrasekhar SS, Rubinstein RY, Kwartler JA, et al. Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol Head Neck Surg 2000; 122: 521-528.
12. Hou D, Wu H, Yang J, Zhang P, Zhang S, Chen J., [Dexamethasone pharmacokinetics in perilymph of guinea pig after different topical administrations]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2005; 19: 307-310.
13. Li S, Gong S, Chen J, Lu H, Wang J,. [Pharmacokinetics of the methylprednisolone, dexamethasone and hydrocortisone in the inner ear after administered via round window]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2005; 19: 24-26.
14. Bird PA, Begg EJ, Zhang M, Keast AT, Murray DP, Balkany TJ,. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otol Neurotol 2007; 28: 1124-1130.
15. Plontke SK, Mikulec AA, Salt AN,. Rapid clearance of methylprednisolone after intratympanic application in humans. Comment on:, Bird PA, Begg EJ, Zhang M, et al. Intratympanic versus intravenous delivery of methyl prednisolone to cochlear perilymph. Otol Neurotol 2007;28:1124-1130. Otol Neurotol 2008;29: 732-733.
16. Chen G, Hou SX, Liu J, Luan JG, Zhang Y., [In vivo distribution and pharmacokinetics of dexamethasone sodium phosphate thermosensitive in situ gel following intratympanic injection]. Sichuan Da Xue Xue Bao Yi Xue Ban 2006; 37: 456-459.
17. Endo T, Nakagawa T, Kita T, et al. Novel strategy for treatment of inner ears using a biodegradable gel. Laryngoscope 2005; 115: 2016-2020.
18. Kelly RM, Meyer JD, Matsuura JE, et al. In vitro release kinetics of gentamycin from a sodium hyaluronate gel delivery system suitable for the treatment of peripheral vestibular disease. Drug Dev Ind Pharm 1999; 25: 15-20.
19. Paulson DP, Abuzeid W, Jiang H, Oe T, OMalley BW, Li D., A novel controlled local drug delivery system for inner ear disease. Laryngoscope 2008; 118: 706-711.
20. Tamura T, Kita T, Nakagawa T, et al. Drug delivery to the cochlea using PLGA nanoparticles. Laryngoscope 2005; 115: 2000-2005.
21. Wang X, Fernandez R, Dellamary L, et al. Pharmacokinetic of dexamethasone solution following intratympanic injection in guinea pig and sheep. Audiol Neurotol 2011; 16: 233-241.
22. Czock D, Keller F, Rasche FM, Haussler U,. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005; 44: 61-98.
23. Kim SH, Kim KX, Raveendran NN, Wu T, Pondugula SR, Marcus DC,. Regulation of ENaC-mediated sodium transport by glucocorticoids in Reissners membrane epithelium. Am J Physiol Cell Physiol 2009; 296: C544-557.
24. Pondugula SR, Raveendran NN, Ergonul Z, et al. Glucocorticoid regulation of genes in the amiloride-sensitive sodium transport pathway by semicircular canal duct epithelium of neonatal rat. Physiol Genomics 2006; 24: 114-123.